公开(公告)号：US20180209980A1

公开(公告)日：2018-07-26

申请号：US15934242

申请日：2018-03-23

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Yasuhiro Funahashi ,  Tadashi Kadowaki ,  Junji Matsui ,  Jason S. Simon ,  Lucy Xu

IPC: G01N33/574 ,  C12Q1/6886 ,  A61K31/47

CPC classification number: G01N33/57407 ,  A61K31/47 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/156 ,  G01N33/57438

Abstract: Biomarkers are provided that are predictive of a subject's responsiveness to a therapy comprising lenvatinib or a pharmaceutically acceptable salt thereof (e.g., lenvatinib mesylate). The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having cancer (e.g., thyroid cancer, kidney cancer), suspected of having cancer, or at risk of developing cancer.

公开(公告)号：US11598776B2

公开(公告)日：2023-03-07

申请号：US15934242

申请日：2018-03-23

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Yasuhiro Funahashi ,  Tadashi Kadowaki ,  Junji Matsui ,  Jason S. Simon ,  Lucy Xu

IPC: G01N33/53 ,  G01N33/574 ,  C12Q1/6886 ,  A61K31/47

Abstract: Biomarkers are provided that are predictive of a subject's responsiveness to a therapy comprising lenvatinib or a pharmaceutically acceptable salt thereof (e.g., lenvatinib mesylate). The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having cancer (e.g., thyroid cancer, kidney cancer), suspected of having cancer, or at risk of developing cancer.